drugset / Trial / NCT03789318

Study in Subjects Undergoing Complete Abdominoplasty

NCT03789318

Phase 2 Completed 54 enrolled Concentric Analgesics
RandomizedParallel-groupTriple-blindTreatment

Summary

Phase 2, single center, randomized, double-blind, placebo-controlled, parallel design study of CA-008 vs. placebo in subjects undergoing an elective C-ABD under general anesthesia supplemented with a bupivacaine hydrochloride (HCl)transverse abdominis plane (TAP) block.

Timeline

Start
2018-12-03
Primary completion
2019-05-16
Completion
2019-06-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator vocacapsaicin Small molecule 5 mg Other
Comparator vocacapsaicin Small molecule 10 mg Other
Comparator vocacapsaicin Small molecule 15 mg Other
Comparator Acetaminophen Small molecule 1000 mg Intravenous
Comparator Bupivacaine Other / unclassified 150 mg Other
Comparator Fentanyl Other / unclassified 100 ug Intravenous
Comparator Hydromorphone Other / unclassified 0.02 mg/kg Intravenous
Comparator Oxycodone Other / unclassified 5 mg Oral
Comparator Oxycodone Other / unclassified 10 mg Oral

Indications

No indication recorded.